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Functional Repair of Rat Corticospinal Tract Lesions Does Not Require 
Permanent Survival of an Immunoincompatible Transplant
Ying Li, Daqing Li, and Geoffrey Raisman
Spinal Repair Unit, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, Queen Square, London, UK
Cell transplantation is one of the most promising strategies for repair of human spinal cord injuries. Animal stud-
ies from a number of laboratories have shown that transplantation of olfactory ensheathing cells cultured from 
biopsies of the olfactory bulb mediate axonal regeneration and remyelination and restore lost functions in spinal 
cord injuries. For translation from small laboratory experimental injuries to the large spinal cord injuries encoun-
tered in human patients the numbers of cells that can be obtained from a patient’s own olfactory bulb becomes a 
serious limiting factor. Furthermore, removal of an olfactory bulb requires invasive surgery and risks unilateral 
anosmia. We here report that xenografted mouse bulbar olfactory ensheathing cells immunoprotected by daily 
cyclosporine restore directed forepaw reaching function in rats with chronic C1/2 unilateral corticospinal tract 
lesions. Once function had been established for 10 days, cyclosporine was withdrawn. Thirteen out of 13 rats 
continued to increase directed forepaw reaching. Immunohistochemistry shows that in all cases neurofilament-
positive axons were present in the lesion, but that the grafted cells had been totally rejected. This implies that 
once grafted cells have acted as bridges for axon regeneration across the lesion site their continued presence is 
no longer necessary for maintaining the restored function. This raises the possibility that in the future a protocol 
of temporary immunoprotection might allow for the use of the larger available numbers of immunoincompatible 
allografted cells or cell lines, which would avoid the need for removing a patient’s olfactory bulb.
Key words: Xenograft; Olfactory ensheathing cells (OECs); Spinal cord injury; Astrocytes
INTRODUCTION
A number of studies have shown that transplanted 
olfactory ensheathing cells (OECs) can induce axon 
regeneration, remyelination, and restoration of function in 
experimental spinal cord injuries (7,8,10,15,21,22,27,28). 
We have described a localized stereotaxic heat lesion 
completely destroying the adult rat corticospinal tract 
(CST) and partial adjacent medial gray matter unilat-
erally at the C1/2 level. Following this lesion, directed 
forepaw reaching (DFR) on the lesion side was totally 
absent. At 2 months after lesion, injection of a suspen-
sion of a mixture of cultured adult bulbar OECs and 
olfactory nerve fibroblasts (ONFs) restored DFR after 
around 10 days (12).
For translation to clinical application, removal of a 
patient’s olfactory bulb necessitates a transdural endo-
scopic or intracranial approach, with the risk of unilat-
eral anosmia. One way to obtain more cells and to avoid 
the problems of autograft biopsy would be to build up a 
bank of allogeneic cells or cell lines (16). As transplants, 
these would therefore have to cross an immune barrier. A 
number of studies with immunoincompatible grafts have 
shown that xenografted OECs immunoprotected with 
cyclosporine induce axon regeneration and remyelination 
in the spinal cord (10,11,18,19,29).
Clinically, permanent immunosuppression carries many 
disadvantages. In the present experiment we used a mouse 
to rat xenograft paradigm to test whether functions restored 
under transient immunosuppression would remain after the 
immunosuppressive regime was discontinued.
MATERIAL AND METHODS
Experimental Design
A total of 58 locally maintained strain of adult female 
Albino Swiss rats (locally bred, London, UK, body weight 
200–220 g) were used.
Group 1: Twenty unlesioned rats received mouse OEC/
ONF xenografts without immunosuppression. Histology 
was carried out at 4 days (n = 5), 1 (n = 5), 2 (n = 4), 3 (n = 3), 
and 4 weeks (n = 3).
The remaining 38 rats had CST lesions and were tested 
for DFR.
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Group 2: In 11/38 of these rats DFR had not been 
abolished, and they were sacrificed for histology.
Group 3: In 8/38 rats in which DFR was abolished, they 
were left for 10–12 months (as a long-term control to check 
that DFR would not return) before sacrifice and histology.
The remaining 19/38 rats all received mouse OEC/ONF 
xenografts at 8 weeks after the CST lesions. Cyclosporine 
administration was applied immediately and continued 
afterward with daily injections.
Group 4: In 6/19 rats that showed no return of DFR 
at 5 weeks after receiving mouse OEC transplants, they 
were terminated for histology.
Group 5: In the remaining 13/19 rats where DFR 
had returned after receiving mouse OEC transplants, 
cyclosporine injection was continued for a further 10 
days after the day when DFR had returned. Ten days later, 
cyclosporine was stopped, and DFR testing continued for 
two to three times a week until 8 weeks after receiving 
the transplants.
Directed Forepaw Reaching (DFR) and Microsurgery
All animals were handled according to the UK Home 
Office regulations ASPA 5(2) PIL 70/9580 for the care 
and use of laboratory animals, the UK Animals (Scientific 
Procedures) Act 1986 with the ethical approval of the 
UCL Institute for Neurology.
Presurgery. DFR was carried out as previously 
described (12). Briefly the rats were trained to use the 
forepaws to retrieve small pieces of noodles through a slit 
in the front of the cage, with 50 retrievals each session. 
Rats that used both right and left paws (more than 15 
times each) were selected for making the CST lesions.
CST Lesions. Rats were anesthetized with isoflurane 
(Abbott Laboratories Ltd., maidenhead, and Berkshire, 
UK). Unilateral CST lesions were made between C1 and 
C2 vertebrae, using an electrode (LCE; Cosman medical 
Inc., Burlington, mA, USA). The CST and adjacent gray 
matter were destroyed by a heat lesion produced by a 
radiofrequency lesion device (RFG-3C RF; Radionics 
Inc., Burlington, mA, USA) operating at 10 V for 1 min 
as previously described (32).
Postsurgery. DFR testing was resumed 3 days after 
the lesion, two to three times a week. Rats that showed 
complete absence of DFR for 8 weeks were selected to 
receive mouse OEC transplants (Groups 4 and 5). Eight 
rats with complete absence of DFR were maintained up to 
12 months as a long-term control (Group 3).
OEC Culture
The tissue from the outer nerve and glomerular layers of 
the olfactory bulbs of (n = 40) 5-month-old female C57BL/6 
(Harlan Laboratories, Bicester, Oxfordshire, UK) was 
trypsinized (0.1%; Worthington Biochemical Corporation, 
Lakewood, NJ, USA) for 15 min at 37°C and plated on 
to 35-mm Nunc™ dishes (Thermo Fisher Scientific UK, 
Hertfordshire, UK) coated with poly-d-lysine (Sigma-
Aldrich, Dorset, UK). The cells were maintained for 15–16 
days in DmEm-F12 (Life Technologies Ltd, Paisley, UK) 
medium including with 10% fetal calf serum (3133-028; 
Gibco, Paisley, UK). The OECs were identified by p75 
immunostaining [anti-nerve growth factor receptor anti-
body, extracellular, clone 192-IgG (mAB365); millipore 
Ltd Hertfordshire, UK], and the ONFs by fibronectin (FN) 
immunostaining [polyclonal rabbit anti-human fibronectin 
(A0245; Dako Ltd, Cambridgeshire, UK)].
Transplantation
Two days before transplantation the cells were trans-
fected with a GFP gene harboring lentiviral construct 
(4,17,24). The cell suspension was made up at a final 
concentration of 25 × 106/ml in DmEm-F12 without FCS. 
Four microliters of the suspension (around 100,000 cells) 
were injected into the lesion site via a glass micropipette 
with a 100- to 120-µm internal tip diameter. Immediately 
after transplantation, cyclosporine (Novartis, Surrey, UK) 
made up at 15 mg/ml in 20% Tween 80 solution (Sigma-
Aldrich) at a dosage of 6 mg/kg with 100% ethanol 
(VWR, Fontenay Sous Bois, France) was delivered intra-
peritoneally (IP) via microfine insulin syringes (BD Ltd, 
Dun Laoghaire, Ireland) and repeated daily. DFR testing 
was restarted 3 days after the transplantation and main-
tained two to three times weekly.
Immunohistochemistry
Rats were perfused with 4% paraformaldehyde (TAAB 
Laboratories Equipment Ltd, Reading, UK) under termi-
nal anesthesia [for details, see Keyvan-Fouladi et al. (12)]. 
Coronal or horizontal cryostat sections, 16 µm, were cut 
and immunostained for GFP/NF (neurofilament, rabbit 
anti-H+L chain NF 1:500; Invitrogen, Paisley, UK); glial 
fibrillary acidic protein (GFAP/NF) (mouse anti-GFAP 
1:1,000, rabbit anti-H+L chain NF 1:500; Invitrogen); 
CD45 (mouse anti-CD45 1:500; BD Pharmingen, Oxford, 
UK). The sections were incubated with either Alexa Fluor 
488-, or 546-conjugated goat anti-rabbit, anti-mouse, or 
goat anti-chicken secondary antibodies (1:400; Invitrogen) 
for 2 h at room temperature. Sytox Orange, 0.1 µm (Life 
Technologies Ltd) was used for cell counterstaining. 
Fluorescent images were captured using a Leica confocal 
microscope TCS SP (milton Keynes, UK).
RESULTS
Group 1 (n = 20): Nonlesioned Rats Receiving Mouse 
OEC/ONF Xenografts Without Immune Protection
After 15–16 days in culture the biopsied mouse 
olfactory bulbs yielded a mixture of 60–70% p75+ spin-
dle-shaped bipolar or tripolar OECs and 30–40% FN+ 
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flattened, short-processed multipolar ONFs. This mixture 
was transplanted into the same C1/2 position in intact 
CST as that where the lesions were carried out in the 
other groups.
At 4 days the transplanted cells, identified by the GFP 
labeling, survived well. The transplant area was occupied 
by a compact ovoid hypercellular mass about 1 mm along 
the rostrocaudal axis of the host CST and around 0.3 mm 
wide. Within the transplant the cells were elongated to 
around 100 µm and, presumably following the surround-
ing mechanical forces, were orientated in parallel to the 
host CST (Fig. 1A).
At 1 week the numbers of GFP-labeled cells were 
reduced to around 30% of those seen at 4 days. The major-
ity of cells had lost their elongated longitudinal pattern 
and appeared to be breaking up into irregular blob-like 
shapes (Fig. 1B). The background was densely hypervas-
cular with hollow cuffed areas suggesting an influx of 
host immunocytes and perivascular cuffing.
At 2, 3, and 4 weeks no GFP-labeled cells were pres-
ent in any part of the transplanted area, which retained the 
hypercellularity and the hollow vascular areas (Fig. 1C). 
At 2 weeks immunostaining of CD45 (leukocyte common 
antigen) showed cells intimately associated with the vessel 
walls, suggesting diapedesis of immunocytes infiltrating 
the entire transplant mass. Thirty-eight rats (Groups 2–5) 
were chosen for DFR on the basis that on 50 trials the DFR 
was comparable on the two sides (maximum imbalance 
35/15). Unilateral C1/2 CST lesions were performed. DFR 
was tested twice weekly from 3 days after operation.
Group 2: Rats With Failed CST Lesions (n = 11)
In 11 of these rats DFR started to return within 2 
weeks. These rats were sacrificed, and the histology con-
firmed that in all 11 cases the destruction of the CST was 
incomplete. The remaining 27 rats (Groups 3–5) showed 
complete loss of DFR at 8 weeks after operation.
Group 3: Rats Confirming Long-Term Persistence 
of Loss of DFR (n = 8)
In the eight rats of this group DFR testing was con-
tinued two to three times a week for 10 months (n = 3) or 
12 months (n = 5). At no time was there any spontaneous 
recovery of DFR on the lesioned side in any of these 
eight rats. Even at the longer survivals none of the eight 
rats showed any diminution of DFR on the unlesioned 
side. Immunostaining confirmed that all these rats had 
complete destruction of the CST with partial destruc-
tion of the adjacent gray matter and in two cases spread-
ing into part of the ventral column. Immunostaining 
for astrocytes (GFAP) and axons (neurofilament, NF) 
showed that the lesion center was completely devoid of 
any trace of NF staining and was completely walled off 
from the NF+ axons of the surrounding spinal tissue by 
a thick layer of scarred GFAP+ astrocytes (Fig. 1E). The 
remaining 19 rats with no DFR at 8 weeks after lesion 
received mouse OEC/ONF mixtures transplanted into 
the lesion site followed by immunoprotection by daily 
cyclosporine (Groups 4 and 5). DFR testing was resumed 
3 days after receiving the transplants and carried out two 
to three times a week.
Group 4: Rats With Grafts Failing to Restore DFR
Six of these cyclosporine-treated rats in which DFR 
had not returned after 5 weeks were terminated. Immuno-
histochemistry showed that all six had complete destruc-
tion of the CST and partial destruction of the adjacent gray 
matter, but no transplanted cells and no NF staining were 
present in the CST lesion center, which was walled off by a 
heavy GFAP+ astrocytic scar.
GFP labeling showed that under cyclosporine treat-
ment the xenografted mouse cells had survived well, 
forming compact masses elongated along the rostrocaudal 
axis of the host spinal cord (as in the short-term animals 
of Group 1). These six transplants were located outside 
the scar walling off the CST lesion area and were there-
fore not in a position to bridge the lesion. Two transplants 
were located in the ascending dorsal column above the 
CST, one was in the ventral spinal cord, and three were 
in the gray matter adjacent to the CST (Fig. 1D). These 
transplants had induced the ingrowth of local NF+ axons 
from the surrounding area.
Group 5: Rats With Return of DFR (n = 13) With 
Mouse OEC/ONF Xenografts Initially Protected 
by Cyclosporine, Which Was Later Withdrawn
In 13 rats the cyclosporine-protected mouse OEC/ONF 
transplants had restored DFR within 2 weeks (n = 11) 
and 3 weeks (n = 2). Once DFR had been reestablished, 
cyclosporine and DFR testing were continued for a fur-
ther 10 days, at which point cyclosporine administration 
was terminated and testing continued until 8 weeks after 
the time of transplantation. In all 13 rats DFR continued 
for 5–6 weeks after withdrawal of cyclosporine, showing 
a continuous increase (Fig. 2).
The histology showed that all the spinal cords in 
this group had complete destruction of CST and partial 
destruction of the adjacent gray matter as in Groups 3 
and 4. As in the rats of Group 1 (Fig. 1C), at 3 weeks 
after transplantation, none of the xenografted cells had 
survived. However, double immunostaining of GFAP/NF 
showed that in every case NF+ axons were seen travers-
ing the lesion center (Fig. 1G–J). Numerically there were 
317.14 ± 35.62 NF+ fibers per section in the n = 7 spinal 
cords cut in cross section [this was surprisingly close to 
the estimate of 320 regenerating axons in our previous 
rat-to-rat OEC transplants into complete CST lesions 
(12)]. The GFAP+ scar tissue was less dense than in the 
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cases with lesion alone (Group 3), with some astrocytes 
extending fine processes into the margins of the lesion.
DISCUSSION
Olfactory ensheathing cells accompany the olfactory 
nerves from their origin in the olfactory mucosa all the 
way through the cribriform plate to their intracranial 
termination in the olfactory bulb (5,23). Unfortunately, 
with our current procedures cultures from the mucosal 
area yield much smaller proportions of OECs (13) than 
those from the bulb. In straight comparisons with bulbar-
sourced cultures, transplantation of mucosal-sourced 
Figure 1. Lesions and transplanted OECs. (A, B, C) Group 1. mouse OECs transplanted into rat CST, no cyclosporine, survival time, 
4 days in (A), 1 week in (B), and 3 weeks in (C). GFP labeling, green; Sytox Orange nuclear counterstaining, red. (D) Group 4. Failed 
restoration of DFR, the OECs not located in the lesion. GFP labeling, green; GFAP immunostaining, red. Survival time, 13 weeks 
(8 weeks after CST lesion, 5 weeks after the transplantation) with daily cyclosporine injection. (E, F) Group 3. Long-term complete 
lesions showing no recovery of DFR. NF/GFAP double immunostaining. NF, red; GFAP, green. Survival time, 10 months. (F) High 
power. (G–J) Group 5. Restoration of DFR after withdrawal temporary immunoprotection. Complete destruction of the xenografted 
cells. NF/GFAP double staining. NF, red; GFAP, green. Survival time, 16 weeks (8 weeks after CST lesion, 8 weeks after the trans-
plantation). (H) High power. (A–C, I, J) Horizontal sections; (D–H) cross sections. Scale bars: 100 µm (A, B, D), 50 µm (C, F, H, J), 
200 µm (E, G, I).
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cultures was ineffective in inducing regeneration of cut 
axons in rat CST (31), rat dorsal roots (9), and in three 
cases in a human clinical trial (25), even after expansion 
by added growth factors (3,6). It is not clear whether this 
reflects the lower proportions of OECs or an intrinsic dif-
ference between the OECs at these two levels (30).
To the best of our knowledge the only spinal injured 
patient who has received autologous bulbar OECs showed 
a pattern of functional recovery highly suggestive of fiber 
regeneration across the injury site (26). This patient had 
a near complete severance of the midthoracic spinal cord 
with stump separation of 7–8 mm. In his case 500,000 
cells were available from culture of a single olfactory 
bulb. As this number of cells was insufficient to form a 
bridge across an injury of this size, the cells were injected 
into the margins of the stumps, and bridging was provided 
by grafting peripheral nerve strips.
The mechanics of future clinical cell transplantation 
would be greatly enhanced if larger numbers of cells were 
available. Allografts using banks of human bulbar OECs 
or cell lines would provide an attractive possibility to 
address this problem and would also avoid the drawbacks 
of having to source cells from the patient’s own olfactory 
bulb (16).
Protection of immunoincompatible grafts involves all 
the side effects of requiring the use of immunosuppres-
sive drug regimes. Such permanent immunosuppression 
is unavoidable in situations where the grafted tissue must 
survive to carry out an essential function (as heart, kidney, 
or pancreatic insulin-secreting cells). However, the recov-
ery of function in the rat CST lesion model depends on new 
fiber connections being formed by the host axons. Although 
this recovery is mediated by the transplanted OECs, it is 
not clear whether the OECs need to be present beyond the 
period of providing a bridge for fiber regeneration.
To examine this we here describe a mouse to rat xeno-
graft paradigm. We confirm (12,32) that after total unilat-
eral destruction of the dorsal CST and the adjacent medial 
gray matter at the C1/2 level there was no return of DFR 
for up to 12 months [cf., e.g., (2,20)]. The present series 
also confirms that unless the transplants form a bridge 
across the lesion area there is no return of function.
In all 13 rats with CST lesions leading to loss of DFR 
the transplantation of immunoprotected mouse OEC/ONF 
xenografts mediated recovery of DFR. This confirms a 
number of previous studies showing that reparative OEC 
signaling mechanisms are conserved across widely dif-
ferent species (10,11,18,19,29).
In all these rats the restored function was maintained 
after the grafted cells had been completely rejected by an 
immune attack following removal of the immunosuppres-
sive regime. Thus, once the OECs have restored function, 
their continued presence is not required for the function 
to be maintained.
Despite the intimacy of the association between the 
transplanted OECs (14) and the regenerating fibers, the 
rejection mechanism acts with such precision that a func-
tionally effective number of regenerating CST fibers 
survived an immune attack completely destroying the 
xenografted mouse OECs. Histological analysis shows 
that the return of function had been mediated by the 
2–300 fibers present in the lesion center after rejection 
of the xenografted mouse cells. This is comparable to the 
number of CST fibers, which restored DFR in a previous 
study (12).
In a similar study (1) researchers showed that rat Schwann 
cells xenografted into mouse peripheral nerve under immu-
nosuppressive conditions myelinated the host fibers and that 
the host fibers survived subsequent rejection of the foreign 
myelinating cells (Aguayo personal communication).
Figure 2. maintained function after rejection of xenografts. Number of directed forepaw reaches (DFR, ordinate, mean ± SD) in the 13 
rats of Group 5, which had complete absence of DFR for 8 weeks after an ipsilateral corticospinal tract lesion (Les) and return of DFR 
after mouse OEC/ONF xenografts (TR) initially protected by daily cyclosporine. DFR continued to increase in all rats after withdrawal 
of cyclosporine (CS/wd) at 10 days after the first return of DFR. Time scale, abscissa in weeks.
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The importance of our present finding is that it opens 
the possibility of using transient immunoprotection of 
allografted cells. For the surgical repair of large human 
spinal cord injuries the ability to use allografted cells or 
cell lines could provide an approach to getting round the 
numerical restriction of autologously sourced cells.
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